|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Johns Hopkins University, Baltimore, MD. Supported by grant HL-50504 from the National Institutes of Health.
Correspondence to: David B. Pearse, MD, Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224
Ischemia and reperfusion (IR) of isolated sheep lungs caused polymorphonuclear leukocyte (PMN) sequestration, pulmonary hypertension secondary to thromboxane (TX), edema, and increased vascular permeability.1 PMN depletion attenuated this injury, suggesting that PMN-derived O2 radicals were involved.2 Apocynin (Apo) is a methoxy-substituted catechol that requires activation by myeloperoxidase to inhibit the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and thus prevents O2- production from activated PMN leukocytes. To determine the effect of Apo in IR injury, we subjected 20 sheep lungs to 30 min of ischemia and 180 min of reperfusion with blood. We injected 3 mM, 0.3 mM, 0.03 mM Apo, or diluent (n = 5 each) into the pulmonary artery early in ischemia and the reservoir before reperfusion. Peak pulmonary artery pressure, peak perfusate TXB2 concentration, and the reflection coefficient for albumin were measured (Table 1) . The ability of Apo to inhibit in vitro O2- production from zymosan-activated sheep PMN leukocytes was also assessed (n = 3).
|
References
This article has been cited by other articles:
![]() |
I. Rubio-Gayosso, S. H. Platts, and B. R. Duling Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2247 - H2256. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Takase, L. Lerond, J. J. Bergan, and G. W. Schmid-Schonbein Enhancement of reperfusion injury by elevation of microvascular pressures Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1387 - H1394. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |